Turning fat into life.
HekeTiss is a pioneering cell therapy biotech focused on developing patent-backed, off-the-shelf allogeneic stem cell therapies to accelerate the regeneration of damaged skin and restore skin health. Founded in 2021 as a spin-off from UNIGE and HUG, HekeTiss developed TrophiPatch, a first-of-its-kind skin patch derived from functionally enhanced donor fat stem cells. TrophiPatch is designed to regenerate blood vessels in chronic wounds, an essential factor for superior healing. Convenient and easy to apply, the patch naturally resorbs, providing a unique and effective solution for wounds that resist conventional treatments.
07.05.2025
Lightium wins the 32nd Prix Strategis (startupticker.ch)
02.04.2025
Prix Strategis 2025 Finalists unveiled (startupticker.ch)
05.11.2024
Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)
28.08.2024
Innosuisse Innovation Council awards seven new startups (startupticker.ch)
25.06.2024
CERN and UNIGE Spinoffs awarded FIF Funding (startupticker.ch)
23.08.2024
Awarded with the Innosuisse Certificate "ready for sustainable growth"
09.07.2024
Secured first investors
01.04.2024
Completed tech transfer in GMP labs, now ready for clinical-grade production of TrophiPatch.
21.03.2023
Efficacy successfully demonstrated in animal proof-of-concept studies.
27.07.2022
Patent PCT/EP2020/076083 entered national phases in the EU and US.
No Jobs
Office de Promotion des Industries et des Technologies - Rencontre avec Nicolò Brembilla et Olivier Preynat-Seauve co-fondateurs d'HekeTiss
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Website:
www.heketiss.ch
Headquarter:
Plan-les-Ouates
Foundation Date:
November 2021
Technology:
Sectors: